EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study

Darryl P Leong, Ali Zhang, Jessica A Breznik iD, Rumi Clare, Angela Huynh, Maha Mushtaha, Sumathy Rangarajan, Hannah Stacey, Paul Y Kim iD, Mark Loeb, Judah A Denburg, Dominik Mertz und 5 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0281673 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Darryl P Leong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: McMaster University, Michael G. DeGroote Institute for Infectious Disease Research, McMaster University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The dosing interval of a primary vaccination series can significantly impact on vaccine immunogenicity and efficacy. The current study compared 3 dosing intervals for the primary vaccination series of the BNT162b2 mRNA COVID-19 vaccine, on humoral immune response and durability against SARS-CoV-2 ancestral and Beta variants up to 9 months post immunization.

Methods

Three groups of age- and sex-matched healthcare workers (HCW) who received 2 primary doses of BNT162b2 separated by 35-days, 35–42 days or >42-days were enrolled. Vaccine induced antibody titers at 3 weeks, 3 and 6–9 months post-second dose were assessed.

Results

There were 309 age- and sex-matched HCW (mean age 43 [sd 13], 58% females) enrolled. Anti-SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibody titers showed significant waning in levels beyond 35 days post first dose. The second dose induced a significant rise in antibody titers, which peaked at 3 weeks and then declined at variable rates across groups. The magnitude, consistency and durability of response was greater for anti-Spike than anti-RBD antibodies; and for IgG than IgA or IgM. Compared to the shorter schedules, a longer interval of >42 days offered the highest binding and neutralizing antibody titers against SARS-CoV-2 ancestral and Beta (B1.351) variants beyond 3 months post-vaccination.

Conclusions

This is the first comprehensive study to compare 3 dosing intervals for the primary vaccination of BNT162b2 mRNA COVID-19 vaccine implemented in the real world. These findings suggest that delaying the second dose beyond 42 days can potentiate and prolong the humoral response against ancestral and Beta variants of SARS-CoV-2 up to 9 months post-vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19FemaleHumansAdultMaleBNT162 VaccineImmunity, HumoralProspective StudiesSARS-CoV-2Health PersonnelRNA, MessengerAntibodies, NeutralizingImmunoglobulin AImmunoglobulin GImmunoglobulin MAntibodies, ViralVaccinationmRNA Vaccines

Substanzen

COVID-19 VaccinesBNT162 VaccineRNA, MessengerAntibodies, NeutralizingImmunoglobulin AImmunoglobulin GImmunoglobulin MAntibodies, ViralmRNA Vaccines

Autor:innen und Institutionen

  • Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.
  • Department of Biochemistry & Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada.
  • McMaster Institute for Research on Aging, McMaster University, Hamilton, Ontario, Canada.

ORCID-Profile: Jessica A Breznik, Paul Y Kim, Dawn M E Bowdish, MyLinh Duong

Förderung

  • McMaster University
  • Michael G. DeGroote Institute for Infectious Disease Research, McMaster University

Zitieren

APA

Leong, D. P., Zhang, A., Breznik, J. A., Clare, R., Huynh, A., Mushtaha, M., Rangarajan, S., Stacey, H., Kim, P. Y., Loeb, M., Denburg, J. A., Mertz, D., Chagla, Z., Nazy, I., Miller, M. S., Bowdish, D. M. E., & Duong, M. (2023). Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0281673

Vancouver

Leong DP, Zhang A, Breznik JA, Clare R, Huynh A, Mushtaha M, et al. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. PLOS ONE. 2023. doi:10.1371/journal.pone.0281673

BibTeX
@article{Leong2023,
  author = {Leong, Darryl P and Zhang, Ali and Breznik, Jessica A and Clare, Rumi and Huynh, Angela and Mushtaha, Maha and Rangarajan, Sumathy and Stacey, Hannah and Kim, Paul Y and Loeb, Mark and Denburg, Judah A and Mertz, Dominik and Chagla, Zain and Nazy, Ishac and Miller, Matthew S and Bowdish, Dawn M E and Duong, MyLinh},
  title = {Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0281673}
}
Kostenlos starten →